{"id":"https://openalex.org/W3083047743","doi":"https://doi.org/10.1158/1538-7445.am2020-3295","title":"Abstract 3295: Vitiligo and other clinical melanocyte-related adverse events following tebentafusp (IMCgp100) exposure in patients with uveal melanoma","display_name":"Abstract 3295: Vitiligo and other clinical melanocyte-related adverse events following tebentafusp (IMCgp100) exposure in patients with uveal melanoma","publication_year":2020,"publication_date":"2020-08-15","ids":{"openalex":"https://openalex.org/W3083047743","doi":"https://doi.org/10.1158/1538-7445.am2020-3295","mag":"3083047743"},"language":"en","primary_location":{"id":"doi:10.1158/1538-7445.am2020-3295","doi":"https://doi.org/10.1158/1538-7445.am2020-3295","is_oa":false,"landing_page_url":"https://doi.org/10.1158/1538-7445.am2020-3295","pdf_url":null,"source":{"id":"https://openalex.org/S168522863","display_name":"Cancer Research","issn_l":"0008-5472","issn":["0008-5472","1538-7445"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["anvur-scientific","cwts-core","dongbi-a","doyens","jufo-3","ki-jl-3","medline","norway-2","poland-200","russia-white-list-1","vabb-shw"],"host_organization":"https://openalex.org/P4310320273","host_organization_name":"American Association for Cancer Research","host_organization_lineage":["https://openalex.org/P4310320273"],"host_organization_lineage_names":["American Association for Cancer Research"],"type":"journal"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Cancer Research","raw_type":"journal-article"},"volume":null,"type":"conference-abstract","is_traditional":false,"indexed_in":["crossref"],"open_access":{"is_oa":false,"oa_status":"closed","oa_url":null,"any_repository_has_fulltext":false},"authorships":[{"author_position":"first","author":{"id":"https://openalex.org/A5034349977","display_name":"Marlana M. Orloff","orcid":"https://orcid.org/0000-0001-9460-2587","observed_orcids":["https://orcid.org/0000-0001-9460-2587"]},"institutions":[{"id":"https://openalex.org/I149251103","display_name":"Thomas Jefferson University","ror":"https://ror.org/00ysqcn41","country_code":"US","type":"education","lineage":["https://openalex.org/I149251103"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Marlana Orloff","raw_affiliation_strings":["1Thomas Jefferson University, Philadephia, PA;"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"1Thomas Jefferson University, Philadephia, PA;","institution_ids":["https://openalex.org/I149251103"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5075295348","display_name":"Joseph J. Sacco","orcid":"https://orcid.org/0000-0003-2591-9796","observed_orcids":["https://orcid.org/0000-0003-2591-9796"]},"institutions":[{"id":"https://openalex.org/I146655781","display_name":"University of Liverpool","ror":"https://ror.org/04xs57h96","country_code":"GB","type":"education","lineage":["https://openalex.org/I146655781"]}],"countries":["GB"],"is_corresponding":false,"raw_author_name":"Joseph J. Sacco","raw_affiliation_strings":["2University of Liverpool, Liverpool; Clatterbridge Cancer Centre, Wirral, United Kingdom;"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"2University of Liverpool, Liverpool; Clatterbridge Cancer Centre, Wirral, United Kingdom;","institution_ids":["https://openalex.org/I146655781"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5085499539","display_name":"Paul Nathan","orcid":"https://orcid.org/0000-0002-2327-3250","observed_orcids":["https://orcid.org/0000-0002-2327-3250","https://orcid.org/0000-0002-5612-8439"]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Paul Nathan","raw_affiliation_strings":["3Mount Vernon Cancer Centre, London, United Kingdom;"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"3Mount Vernon Cancer Centre, London, United Kingdom;","institution_ids":[]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5109184686","display_name":"Chris Holland","orcid":null,"observed_orcids":[]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Chris Holland","raw_affiliation_strings":["4Immunocore LLC, Rockville, MD;"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"4Immunocore LLC, Rockville, MD;","institution_ids":[]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5065751345","display_name":"Chris Cohen","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I4210091819","display_name":"Immunocore (United States)","ror":"https://ror.org/00czwhy51","country_code":"US","type":"company","lineage":["https://openalex.org/I4210091819","https://openalex.org/I4210104024"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Chris Cohen","raw_affiliation_strings":["5Immunocore LLC, Conshohocken, PA;"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"5Immunocore LLC, Conshohocken, PA;","institution_ids":["https://openalex.org/I4210091819"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5109471232","display_name":"Jane V. Harper","orcid":null,"observed_orcids":[]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Jane Harper","raw_affiliation_strings":["6Immunocore Ltd, Oxford, United Kingdom;"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"6Immunocore Ltd, Oxford, United Kingdom;","institution_ids":[]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5112689629","display_name":"Shaad Essa Abdullah","orcid":"https://orcid.org/0000-0003-0776-7477","observed_orcids":["https://orcid.org/0000-0003-0776-7477"]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Shaad E. Abdullah","raw_affiliation_strings":["4Immunocore LLC, Rockville, MD;"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"4Immunocore LLC, Rockville, MD;","institution_ids":[]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5053828591","display_name":"Takami Sato","orcid":"https://orcid.org/0000-0003-2221-0415","observed_orcids":["https://orcid.org/0000-0003-2221-0415"]},"institutions":[{"id":"https://openalex.org/I149251103","display_name":"Thomas Jefferson University","ror":"https://ror.org/00ysqcn41","country_code":"US","type":"education","lineage":["https://openalex.org/I149251103"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Takami Sato","raw_affiliation_strings":["1Thomas Jefferson University, Philadephia, PA;"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"1Thomas Jefferson University, Philadephia, PA;","institution_ids":["https://openalex.org/I149251103"]}]},{"author_position":"last","author":{"id":"https://openalex.org/A5086473468","display_name":"Richard D. Carvajal","orcid":"https://orcid.org/0000-0002-3796-1118","observed_orcids":["https://orcid.org/0000-0002-3796-1118"]},"institutions":[{"id":"https://openalex.org/I2799503643","display_name":"Columbia University Irving Medical Center","ror":"https://ror.org/01esghr10","country_code":"US","type":"healthcare","lineage":["https://openalex.org/I2799503643"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Richard D. Carvajal","raw_affiliation_strings":["7Columbia University Irving Medical Center, New York, NY"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"7Columbia University Irving Medical Center, New York, NY","institution_ids":["https://openalex.org/I2799503643"]}]}],"institutions":[],"countries_distinct_count":2,"institutions_distinct_count":4,"corresponding_author_ids":[],"corresponding_institution_ids":[],"apc_list":null,"apc_paid":null,"fwci":null,"has_fulltext":false,"cited_by_count":5,"citation_normalized_percentile":null,"cited_by_percentile_year":null,"biblio":{"volume":"80","issue":"16_Supplement","first_page":"3295","last_page":"3295"},"is_retracted":false,"is_paratext":false,"is_xpac":false,"primary_topic":{"id":"https://openalex.org/T10158","display_name":"Cancer Immunotherapy and Biomarkers","score":0.513700008392334,"subfield":{"id":"https://openalex.org/subfields/2730","display_name":"Oncology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},"topics":[{"id":"https://openalex.org/T10158","display_name":"Cancer Immunotherapy and Biomarkers","score":0.513700008392334,"subfield":{"id":"https://openalex.org/subfields/2730","display_name":"Oncology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},{"id":"https://openalex.org/T11328","display_name":"Ocular Oncology and Treatments","score":0.4203999936580658,"subfield":{"id":"https://openalex.org/subfields/2731","display_name":"Ophthalmology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},{"id":"https://openalex.org/T11194","display_name":"Ocular Diseases and Beh\u00e7et\u2019s Syndrome","score":0.012799999676644802,"subfield":{"id":"https://openalex.org/subfields/2731","display_name":"Ophthalmology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}}],"keywords":[{"id":"https://openalex.org/keywords/tebentafusp","display_name":"tebentafusp","score":0.9950000047683716},{"id":"https://openalex.org/keywords/uveal-melanoma","display_name":"uveal melanoma","score":0.9089999794960022},{"id":"https://openalex.org/keywords/vitiligo","display_name":"vitiligo","score":0.9509999752044678},{"id":"https://openalex.org/keywords/gp100","display_name":"gp100","score":0.8759999871253967},{"id":"https://openalex.org/keywords/leukotrichia","display_name":"leukotrichia","score":0.8209999799728394},{"id":"https://openalex.org/keywords/hyperpigmentation","display_name":"hyperpigmentation","score":0.9480000138282776},{"id":"https://openalex.org/keywords/overall-survival","display_name":"overall survival","score":0.6669999957084656},{"id":"https://openalex.org/keywords/hla-a-0201","display_name":"HLA-A*0201","score":0.8669999837875366},{"id":"https://openalex.org/keywords/anti-pd-1-therapy","display_name":"anti-PD-1 therapy","score":0.5989999771118164}],"concepts":[{"id":"https://openalex.org/C2779980618","wikidata":"https://www.wikidata.org/wiki/Q180152","display_name":"Vitiligo","level":2,"score":0.8566444516181946},{"id":"https://openalex.org/C2779769559","wikidata":"https://www.wikidata.org/wiki/Q247101","display_name":"Melanocyte","level":3,"score":0.7807733416557312},{"id":"https://openalex.org/C2777658100","wikidata":"https://www.wikidata.org/wiki/Q180614","display_name":"Melanoma","level":2,"score":0.775973379611969},{"id":"https://openalex.org/C71924100","wikidata":"https://www.wikidata.org/wiki/Q11190","display_name":"Medicine","level":0,"score":0.6671398282051086},{"id":"https://openalex.org/C2909381827","wikidata":"https://www.wikidata.org/wiki/Q1641068","display_name":"Skin hyperpigmentation","level":3,"score":0.5805466771125793},{"id":"https://openalex.org/C2776728111","wikidata":"https://www.wikidata.org/wiki/Q1641068","display_name":"Hyperpigmentation","level":2,"score":0.49960803985595703},{"id":"https://openalex.org/C2778570526","wikidata":"https://www.wikidata.org/wiki/Q653197","display_name":"Rash","level":2,"score":0.48663529753685},{"id":"https://openalex.org/C2779053233","wikidata":"https://www.wikidata.org/wiki/Q731235","display_name":"ELISPOT","level":4,"score":0.43360739946365356},{"id":"https://openalex.org/C203014093","wikidata":"https://www.wikidata.org/wiki/Q101929","display_name":"Immunology","level":1,"score":0.4280424118041992},{"id":"https://openalex.org/C16005928","wikidata":"https://www.wikidata.org/wiki/Q171171","display_name":"Dermatology","level":1,"score":0.39883944392204285},{"id":"https://openalex.org/C143998085","wikidata":"https://www.wikidata.org/wiki/Q162555","display_name":"Oncology","level":1,"score":0.3215996026992798},{"id":"https://openalex.org/C502942594","wikidata":"https://www.wikidata.org/wiki/Q3421914","display_name":"Cancer research","level":1,"score":0.3189983367919922},{"id":"https://openalex.org/C147483822","wikidata":"https://www.wikidata.org/wiki/Q103537","display_name":"Antigen","level":2,"score":0.2844560444355011},{"id":"https://openalex.org/C167672396","wikidata":"https://www.wikidata.org/wiki/Q417800","display_name":"CD8","level":3,"score":0.2686924934387207}],"mesh":[],"locations_count":1,"locations":[{"id":"doi:10.1158/1538-7445.am2020-3295","doi":"https://doi.org/10.1158/1538-7445.am2020-3295","is_oa":false,"landing_page_url":"https://doi.org/10.1158/1538-7445.am2020-3295","pdf_url":null,"source":{"id":"https://openalex.org/S168522863","display_name":"Cancer Research","issn_l":"0008-5472","issn":["0008-5472","1538-7445"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["anvur-scientific","cwts-core","dongbi-a","doyens","jufo-3","ki-jl-3","medline","norway-2","poland-200","russia-white-list-1","vabb-shw"],"host_organization":"https://openalex.org/P4310320273","host_organization_name":"American Association for Cancer Research","host_organization_lineage":["https://openalex.org/P4310320273"],"host_organization_lineage_names":["American Association for Cancer Research"],"type":"journal"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Cancer Research","raw_type":"journal-article"}],"best_oa_location":null,"sustainable_development_goals":[{"score":1.0,"id":"https://metadata.un.org/sdg/3","display_name":"Good health and well-being"}],"study_designs":[],"awards":[],"funders":[],"has_content":{"grobid_xml":false,"pdf":false},"content_urls":null,"referenced_works_count":0,"referenced_works":[],"related_works":["https://openalex.org/W3098652024","https://openalex.org/W7106307957","https://openalex.org/W4379339238","https://openalex.org/W7213968927","https://openalex.org/W4322496023","https://openalex.org/W4400645632","https://openalex.org/W4220723947","https://openalex.org/W4387845260","https://openalex.org/W3214459545","https://openalex.org/W4221102042"],"abstract_inverted_index":{"Abstract":[0],"Background":[1],"Tebentafusp,":[2],"a":[3,11,44,54,79,92,292,335,339,344],"TCR-anti-CD3":[4],"bispecific":[5],"fusion":[6],"protein":[7],"designed":[8],"to":[9,82,196,215,280,351,402],"target":[10],"peptide":[12,256],"from":[13],"melanocyte":[14,184],"lineage":[15],"antigen":[16],"gp100,":[17],"has":[18],"shown":[19],"monotherapy":[20],"activity":[21],"in":[22,33,36,53,71,151,243,320,330,385,472],"advanced":[23,366],"cutaneous":[24],"and":[25,38,49,91,109,134,136,145,149,158,189,202,210,229,236,274,309,314,408,462,495],"uveal":[26,475],"melanoma":[27,67,138,235,476],"(UM)":[28],"[1].":[29,63],"gp100":[30],"is":[31,299,391],"expressed":[32],"normal":[34],"melanocytes":[35,130,238,248],"skin":[37,128,190],"hair":[39],"follicles.":[40],"We":[41,99],"previously":[42],"reported":[43,395],"possible":[45],"association":[46,94,103,199],"between":[47,200],"rash":[48,313],"overall":[50],"survival":[51],"(OS)":[52],"Ph":[55],"1/2":[56],"trial":[57,170],"of":[58,73,84,104,114,124,154,161,183,218,259,282,290,296,332,348,362,389,415,480,484],"HLA-A*0201":[59],"patients":[60,115,261,304,322,364,473],"with":[61,75,95,116,143,221,277,305,323,343,365,405,420,474],"UM":[62,367],"Anti-PD1":[64],"therapy":[65],"for":[66,180,206,247,396,411,488],"can":[68,378],"induce":[69],"vitiligo":[70],"10-25%":[72],"patients,":[74],"one":[76,264,371],"study":[77],"showing":[78],"median":[80,278],"time":[81,208,279,413],"onset":[83,281],"126":[85],"days":[86,284],"(range":[87,285],"52":[88],"-":[89],"453)":[90],"potential":[93],"clinical":[96,169,464],"benefit":[97],"[2].":[98],"now":[100],"investigate":[101],"the":[102,121,198,302,374,412,481,485],"melanocyte-related":[105,465],"adverse":[106,466],"events":[107,467],"(MRAEs)":[108],"OS":[110,203],"following":[111,468],"tebentafusp":[112,147,227,377,469],"treatment":[113,298],"UM.":[117],"Methods":[118],"To":[119],"test":[120],"differential":[122,255],"potency":[123,246],"tebentafusp,":[125],"HLA-A2+":[126],"epidermal":[127],"derived":[129,195],"(5":[131],"healthy":[132],"donors)":[133],"gp100+":[135,234,383],"gp100-":[137,241],"cell":[139,156,163],"lines":[140],"were":[141,194],"incubated":[142],"PBMCs":[144],"increasing":[146],"concentrations,":[148],"tested":[150],"IFN\u03b3":[152],"(measure":[153,160],"T":[155,162,231,380],"activation)":[157],"GrB":[159],"mediated":[164],"killing)":[165],"ELISPOT":[166],"assays.":[167],"The":[168,287],"database":[171],"(NCT02570308;":[172],"Ph1":[173],"n=19,":[174],"Ph2":[175],"n=23)":[176],"was":[177,213,249,341],"also":[178],"queried":[179],"AEs":[181],"suggestive":[182],"origin,":[185],"including":[186,268],"vitiligo,":[187],"leukotrichia,":[188],"hyperpigmentation.":[191],"Simon-Makuch":[192],"estimates":[193],"visualize":[197],"MRAEs":[201,267,319,329,390,400],"while":[204,326],"adjusting":[205],"immortal":[207],"bias,":[209],"Mantel-Byar":[211],"method":[212],"used":[214],"estimate":[216],"odds":[217,347],"death":[219,349],"associated":[220,342,404,419],"experiencing":[222,291,338],"MRAEs.":[223],"Results":[224],"In":[225,334],"vitro,":[226],"redirected":[228],"activated":[230],"cells":[232,381,384],"against":[233,382],"skin-derived":[237],"but":[239],"not":[240,355],"melanoma;":[242],"all":[244,321],"cases,":[245],"less":[250],"than":[251,393],"melanoma,":[252],"potentially":[253],"reflecting":[254],"presentation.":[257],"24":[258,303],"42":[260],"(57%)":[262],"developed":[263],"or":[265],"more":[266],"vitiligo/skin":[269],"hypopigmentation":[270],"(28%),":[271],"leukotrichia":[272],"(33%),":[273],"hyperpigmentation":[275],"(21%),":[276],"67":[283],"24-221).":[286],"estimated":[288],"probability":[289],"MRAE":[293,340],"within":[294],"6-months":[295],"continuous":[297],"70%.":[300],"Among":[301],"MRAEs,":[306],"22":[307],"(92%)":[308],"20":[310],"(83%)":[311],"experienced":[312,368],"pruritus,":[315],"respectively.":[316],"Rash":[317],"preceded":[318,328],"both":[324],"events,":[325],"pruritus":[327],"77%":[331],"patients.":[333,386],"post-hoc":[336],"analysis,":[337],"72%":[345],"lower":[346],"compared":[350],"those":[352],"who":[353],"did":[354],"experience":[356],"these":[357],"AEs.":[358],"Conclusion":[359],"Over":[360],"half":[361],"tebentafusp-treated":[363],"at":[369],"least":[370],"MRAE,":[372],"supporting":[373],"hypothesis":[375],"that":[376],"redirect":[379],"This":[387],"rate":[388],"higher":[392],"historically":[394],"anti-PD1":[397],"based":[398],"therapies.":[399],"appear":[401],"be":[403,418],"prior":[406],"rash,":[407],"even":[409],"accounting":[410],"bias":[414],"onset,":[416],"may":[417],"OS.":[421],"1.":[422],"Sato":[423],"T.":[424],"J":[425],"Clin":[426],"Oncol":[427],"36,":[428],"2018,":[429],"suppl,":[430],"9521":[431],"2.":[432],"Hua":[433],"C.":[434],"JAMA":[435],"Dermatol":[436],"2016;152:45-51":[437],"Citation":[438],"Format:":[439],"Marlana":[440],"Orloff,":[441],"Joseph":[442],"J.":[443],"Sacco,":[444],"Paul":[445],"Nathan,":[446],"Chris":[447,449],"Holland,":[448],"Cohen,":[450],"Jane":[451],"Harper,":[452],"Shaad":[453],"E.":[454],"Abdullah,":[455],"Takami":[456],"Sato,":[457],"Richard":[458],"D.":[459],"Carvajal.":[460],"Vitiligo":[461],"other":[463],"(IMCgp100)":[470],"exposure":[471],"[abstract].":[477],"In:":[478],"Proceedings":[479],"Annual":[482],"Meeting":[483],"American":[486],"Association":[487],"Cancer":[489,501],"Research":[490],"2020;":[491],"2020":[492],"Apr":[493],"27-28":[494],"Jun":[496],"22-24.":[497],"Philadelphia":[498],"(PA):":[499],"AACR;":[500],"Res":[502],"2020;80(16":[503],"Suppl):Abstract":[504],"nr":[505],"3295.":[506]},"counts_by_year":[{"year":2025,"cited_by_count":2},{"year":2022,"cited_by_count":3}],"updated_date":"2026-10-16T09:59:22.235173","created_date":"2020-09-11T00:00:00"}